News Summary

OpenAI has been in discussions with the U.S. Food and Drug Administration (FDA) to explore the use of artificial intelligence in speeding up the drug evaluation process. These meetings are part of a broader initiative by the FDA to modernize its operations and reduce the time it takes for new drugs to reach the market. The discussions have centered around a project called cderGPT, which is likely related to the Center for Drug Evaluation and Research. Jeremy Walsh, the FDA’s first-ever AI officer, is leading these talks. The integration of AI in drug evaluation is seen as a way to enhance efficiency, though it is still in the exploratory phase with no contracts signed yet. The potential use of AI in drug evaluations represents a small part of a larger opportunity to leverage technology in healthcare, although it raises questions about data training and model performance.